SAFETY DATA SHEET

Clotrimazole / Gentamicin / Betamethasone
(0.1%) Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Clotrimazole / Gentamicin / Betamethasone (0.1%) Formulation

Manufacturer or supplier's details
Company : MSD
Address : Rua Coronel Bento Soares, 530
          Cruzeiro - Sao Paulo - Brazil  CEP 12730-340
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTeward@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard
Reproductive toxicity : Category 1A
Specific target organ toxicity - repeated exposure : Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)
Short-term (acute) aquatic hazard : Category 1
Long-term (chronic) aquatic hazard : Category 1

GHS label elements in accordance with ABNT NBR 14725 Standard
Hazard pictograms : 

Signal Word : Danger
Hazard Statements : H360D May damage the unborn child.
                    H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.
                    H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements : Prevention:
## P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

**Other hazards which do not result in classification**
None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Substance / Mixture:** Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>White mineral oil (petroleum)</td>
<td>8042-47-5</td>
<td></td>
<td>&gt;= 90 - &lt;= 100</td>
</tr>
<tr>
<td></td>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>Acute toxicity (Oral), Category 4</td>
<td>&gt;= 1 - &lt; 2,5</td>
</tr>
<tr>
<td></td>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>Reproductive toxicity, Category 1A</td>
<td>&gt;= 0,3 - &lt; 1</td>
</tr>
</tbody>
</table>

Specific target organ toxicity - repeated exposure (Oral) (Liver, Kidney, Adrenal gland), Category 2
Short-term (acute) aquatic hazard, Category 1
Long-term (chronic) aquatic hazard, Category 1

Short-term (acute) aquatic hazard, Category 1
Long-term (chronic) aquatic hazard, Category 1
SAFETY DATA SHEET

Clotrimazole / Gentamicin / Betamethasone (0.1%) Formulation

Version 6.2 Revision Date: 27.08.2021 SDS Number: 808837-00015 Date of last issue: 10.10.2020 Date of first issue: 22.07.2016

<table>
<thead>
<tr>
<th>substance</th>
<th>CAS number</th>
<th>Category 1</th>
<th>Category 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betamethasone</td>
<td>378-44-9</td>
<td>Acute toxicity (Inhalation), Category 2</td>
<td>Reproductive toxicity, Category 1B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Specific target organ toxicity - repeated exposure (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland), Category 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Long-term (chronic) aquatic hazard, Category 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;= 0.1 -&lt; 0.25</td>
<td></td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention.

Most important symptoms and effects, both acute and delayed: May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.
**SAFETY DATA SHEET**

**Clotrimazole / Gentamicin / Betamethasone (0.1%) Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

**Specific hazards during fire fighting**

- Exposure to combustion products may be a hazard to health.
- Carbon oxides

**Hazardous combustion products**

- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

**Special protective equipment for fire-fighters**

- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**

- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**

- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g., by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**

- Soak up with inert absorbent material.
- For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

**Technical measures**

- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

**Local/Total ventilation**

- If sufficient ventilation is unavailable, use with local exhaust ventilation.

**Advice on safe handling**

- Do not get on skin or clothing.
- Do not breathe mist or vapors.
- Do not swallow.
- Avoid contact with eyes.
Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil (petroleum)</td>
<td>8042-47-5</td>
<td>TWA (Inhalable particulate matter)</td>
<td>5 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>378-44-9</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin
Wipe limit 10 µg/100 cm² Internal

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

**Personal protective equipment**

**Respiratory protection**
- : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - Filter type: Combined particulates and organic vapor type

**Hand protection**
- : Chemical-resistant gloves

**Eye protection**
- : Wear safety glasses with side shields or goggles.
  - If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
  - Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**
- : Work uniform or laboratory coat.
  - Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
  - Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

- **Appearance** : liquid
- **Color** : No data available
- **Odor** : No data available
- **Odor Threshold** : No data available
- **pH** : No data available
- **Melting point/freezing point** : No data available
- **Initial boiling point and boiling range** : No data available
- **Flash point** : No data available
- **Evaporation rate** : No data available
- **Flammability (solid, gas)** : Not applicable
- **Flammability (liquids)** : No data available
- **Upper explosion limit / Upper** : No data available
SAFETY DATA SHEET

Clotrimazole / Gentamicin / Betamethasone (0.1%) Formulation

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Acute inhalation toxicity: Acute toxicity estimate: > 10 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity: Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:

White mineral oil (petroleum):
Acute oral toxicity: LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity: LD50 (Rabbit): > 2.000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

clotrimazole:
Acute oral toxicity: LD50 (Rat): 708 mg/kg
LD50 (Mouse): 761 mg/kg
LD50 (Rabbit): > 1.000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 0,73 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Mouse): 923 mg/kg

Gentamicin:
Acute oral toxicity: LD50 (Rat): 8.000 - 10.000 mg/kg
LD50 (Mouse): 10.000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 0,2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration): LD50 (Rat): 67 - 96 mg/kg
Application Route: Intravenous
LD50 (Rat): 371 - 384 mg/kg
Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg
Application Route: Intravenous

Betamethasone:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity: LC50 (Rat): 0.4 mg/l
Exposure time: 4 h

Skin corrosion/irritation
Not classified based on available information.

Components:

White mineral oil (petroleum):
Species: Rabbit
Result: No skin irritation

clotrimazole:
Species: Rabbit
Result: No skin irritation

Gentamicin:
Species: Rabbit
Result: Mild skin irritation

Betamethasone:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

White mineral oil (petroleum):
Species: Rabbit
Result: No eye irritation

clotrimazole:
Species: Rabbit
Result: Mild eye irritation
Gentamicin:
Species: Rabbit
Result: Mild eye irritation

Betamethasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:
White mineral oil (petroleum):
Test Type: Buehler Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Gentamicin:
Remarks: No data available

Betamethasone:
Routes of exposure: Dermal
Species: Guinea pig
Result: Weak sensitizer

Germ cell mutagenicity
Not classified based on available information.

Components:
White mineral oil (petroleum):
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Result: negative
- Test Type: in vitro micronucleus test
  Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Rat
  Application Route: Oral
  Result: negative
- Test Type: Mammalian spermatogonial chromosome aberration test (in vivo)
  Species: Hamster
  Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

**Gentamicin:**
Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Result: equivocal

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Intravenous injection
  Result: negative

**Betamethasone:**
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Result: positive

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Oral
  Result: equivocal
SAFETY DATA SHEET

Clotrimazole / Gentamicin / Betamethasone (0.1%) Formulation

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

White mineral oil (petroleum):
Species: Rat
Application Route: Ingestion
Exposure time: 24 Months
Result: negative

clotrimazole:
Species: Rat
Application Route: Oral
Exposure time: 78 weeks
Result: negative

Gentamicin:
Carcinogenicity - Assessment: No data available

Reproductive toxicity
May damage the unborn child.

Components:

White mineral oil (petroleum):
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Skin contact
Result: negative

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

clotrimazole:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 50 mg/kg body weight
Result: Effects on fertility.

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryo-fetal toxicity., No teratogenic effects.
Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 50 mg/kg body weight  
Result: Embryo-fetal toxicity., No teratogenic effects.

Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 200 mg/kg body weight  
Result: No effects on fetal development.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 180 mg/kg body weight  
Result: No effects on fetal development.

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

Gentamicin:  
Effects on fertility: Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Fertility: NOAEL: 20 mg/kg body weight  
Result: No significant adverse effects were reported

Effects on fetal development: Test Type: Embryo-fetal development  
Species: Rabbit  
Developmental Toxicity: NOAEL: 3,6 mg/kg body weight  
Result: No embryo-fetal toxicity.

Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 75 mg/kg body weight  
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: Fetal mortality., No malformations were observed.

Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 50 mg/kg body weight  
Result: Fetal mortality., No malformations were observed.
Reproductive toxicity - Assessment: Positive evidence of adverse effects on development from human epidemiological studies.

Betamethasone:
Effects on fetal development: Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 0.05 mg/kg body weight
Result: Fetotoxicity, Malformations were observed.

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0.42 mg/kg body weight
Result: Malformations were observed.

Species: Mouse
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Result: Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Components:

clotrimazole:
Target Organs Assessment: Liver, Kidney, Adrenal gland
May cause damage to organs through prolonged or repeated exposure.

Gentamicin:
Target Organs Assessment: Kidney, inner ear
Causes damage to organs through prolonged or repeated exposure.

Betamethasone:
Target Organs Assessment: Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Causes damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

**Components:**

White mineral oil (petroleum):

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>160 mg/kg</td>
<td>Ingestion</td>
<td>90 Days</td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>&gt;= 1 mg/l</td>
<td>Inhalation (dust/mist/fume)</td>
<td>4 Weeks</td>
<td>OECD Test Guideline 412</td>
</tr>
</tbody>
</table>

**clotrimazole:**

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>5 - 40 mg/kg</td>
<td>Skin contact</td>
<td>3 Weeks</td>
<td>Skin</td>
<td>Edema, Fissuring, Necrosis, Redness</td>
</tr>
<tr>
<td>Rat</td>
<td>10 mg/kg</td>
<td>Oral</td>
<td>18 Months</td>
<td>Liver, Kidney, Adrenal gland</td>
<td></td>
</tr>
<tr>
<td>Dog</td>
<td>25 mg/kg</td>
<td>Oral</td>
<td>6 - 12 Months</td>
<td>Adrenal gland</td>
<td>Salivation, Lachrymation, Vomiting</td>
</tr>
</tbody>
</table>

**Gentamicin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>3 mg/kg</td>
<td>Intramuscular</td>
<td>12 Months</td>
<td>Kidney</td>
<td>Vomiting, Salivation</td>
</tr>
<tr>
<td>Monkey</td>
<td>50 mg/kg</td>
<td>Subcutaneous</td>
<td>3 Weeks</td>
<td>Kidney, inner ear</td>
<td></td>
</tr>
</tbody>
</table>

Species: Monk
<table>
<thead>
<tr>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 mg/kg</td>
<td>Intramuscular</td>
<td>3 Weeks</td>
<td>Blood, Kidney, inner ear, Liver</td>
</tr>
</tbody>
</table>

**Species:** Rat

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg/kg</td>
<td>10 mg/kg</td>
</tr>
</tbody>
</table>

**Application Route:** Intramuscular

<table>
<thead>
<tr>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>52 Weeks</td>
<td>Kidney, Blood</td>
</tr>
</tbody>
</table>

**Species:** Rat

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 mg/kg</td>
<td>Intramuscular</td>
<td>13 Weeks</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

**Species:** Rabbit

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05 %</td>
<td>Skin contact</td>
<td>10 - 30 d</td>
<td>Pituitary gland, Immune system, muscle</td>
</tr>
</tbody>
</table>

**Species:** Rat

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05 %</td>
<td>Skin contact</td>
<td>8 Weeks</td>
<td>thymus gland</td>
</tr>
</tbody>
</table>

**Species:** Mouse

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1 %</td>
<td>Skin contact</td>
<td>8 Weeks</td>
<td>thymus gland</td>
</tr>
</tbody>
</table>

**Species:** Dog

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05 mg/kg</td>
<td>Oral</td>
<td>28 d</td>
<td>Blood, thymus gland, Adrenal gland</td>
</tr>
</tbody>
</table>

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure**

**Components:**

**clothrimazole:**

Skin contact: Symptoms: Rash, Itching, Blistering, Edema, Redness
Ingestion:
- Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhea

Gentamicin:
- Ingestion:
  - Target Organs: Kidney
  - Target Organs: inner ear
  - Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

Betamethasone:
- Inhalation:
  - Target Organs: Adrenal gland
- Skin contact:
  - Symptoms: Redness, pruritis, Irritation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

White mineral oil (petroleum):
- Toxicty to fish:
  - LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates:
  - EC50 (Daphnia magna (Water flea)): > 100 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants:
  - NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity):
  - NOEC (Oncorhynchus mykiss (rainbow trout)): 1.000 mg/l
  - Exposure time: 28 d
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
  - NOEC (Daphnia magna (Water flea)): 1.000 mg/l
  - Exposure time: 21 d

Clotrimazole:
- Toxicty to fish:
  - LC50 (Brachydanio rerio (zebrafish)): > 0,29 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates:
  - EC50 (Daphnia magna (Water flea)): 0,02 mg/l
  - Exposure time: 48 h
- Toxicity to algae/aquatic plants:
  - EC50 (Desmodesmus subspicatus (green algae)): 0,268 mg/l
  - Exposure time: 72 h
  - NOEC (Desmodesmus subspicatus (green algae)): 0,017 mg/l
  - Exposure time: 72 h

M-Factor (Acute aquatic toxicity):
- 10
### Clotrimazole / Gentamicin / Betamethasone (0.1%) Formulation

**Version** 6.2  
**Revision Date:** 27.08.2021  
**SDS Number:** 808837-00015  
**Date of last issue:** 10.10.2020  
**Date of first issue:** 22.07.2016

#### Toxicity to fish (Chronic toxicity)
- **NOEC** (Onchorhynchus mykiss (rainbow trout)): 0.025 mg/l  
  Exposure time: 32 d  
  Method: OECD Test Guideline 210

#### Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)
- **NOEC** (Daphnia magna (Water flea)): 0.01 mg/l  
  Exposure time: 21 d  
  Method: OECD Test Guideline 211

#### M-Factor (Chronic aquatic toxicity)
- **M-Factor** (Chronic aquatic toxicity): 10

#### Toxicity to microorganisms
- **EC50**: > 10.000 mg/l  
  Exposure time: 3 h  
  Test Type: Respiration inhibition  
  Method: OECD Test Guideline 209

#### Gentamicin:

##### Toxicity to daphnia and other aquatic invertebrates
- **EC50** (Daphnia magna (Water flea)): 86 mg/l  
  Exposure time: 48 h  
  Method: OECD Test Guideline 202

- **LC50** (Americamysis): 30 mg/l  
  Exposure time: 96 h  
  Method: US-EPA OPPTS 850.1035

##### Toxicity to algae/aquatic plants
- **EC50** (Pseudokirchneriella subcapitata (green algae)): 10 µg/l  
  Exposure time: 72 h  
  Method: OECD Test Guideline 201

- **NOEC** (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l  
  Exposure time: 72 h  
  Method: OECD Test Guideline 201

- **EC50** (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l  
  Exposure time: 72 h  
  Method: OECD Test Guideline 201

- **NOEC** (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l  
  Exposure time: 72 h  
  Method: OECD Test Guideline 201

- **M-Factor (Acute aquatic toxicity)**: 100

- **M-Factor (Chronic aquatic toxicity)**: 1

- **Toxicity to microorganisms**:  
  - **EC50**: 288.7 mg/l  
    Exposure time: 3 h  
    Test Type: Respiration inhibition  
    Method: OECD Test Guideline 209

#### Betamethasone:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Americamysis): > 50 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.052 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

NOEC (Oryzias latipes (Japanese medaka)): 0.07 µg/l
Exposure time: 219 d
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity): 1.000

Persistence and degradability

Components:

White mineral oil (petroleum): Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d

Clotrimazole:
Stability in water: Hydrolysis: 50 % (242 d)

Gentamicin:
Biodegradability: Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Gentamicin:
Partition coefficient: n-octanol/water
Betamethasone:
Partition coefficient: n-octanol/water
Mobility in soil
No data available
Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (clotrimazole, Gentamicin)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 964
Packing instruction (passenger aircraft): 964
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)
Class: 9
Packing group: III
Labels: 9
SAFETY DATA SHEET

Clotrimazole / Gentamicin / Betamethasone (0.1%) Formulation

Version 6.2  Revision Date: 27.08.2021  SDS Number: 808837-00015  Date of last issue: 10.10.2020
Date of first issue: 22.07.2016

EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

ANTT
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)
Class : 9
Packing group : III
Labels : 9
Hazard Identification Number : 90

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable
Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

BR / Z8